Text Size

Pooled Analysis of Three MicroShunt Studies in Primary Open-Angle Glaucoma Evaluating Different Concentrations of Applied Mitomycin C

Garcia-Feijoo J.; Batlle J.F.; Aptel F.; Lachkar Y.; Riss I.; Sadruddin O.; Nguyen T.; Beckers H.J.MM


  • 2025
  • Ophthalmol Ther.
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Departamento de Oftalmologia, Universidad Complutense, Hospital Clínico San Carlos, OFTARED, IdISSC, Planta 3, Madrid, Spain; Centro Láser, Santo Domingo, Dominican Republic; Groupe Visis et médipôle Elsan, Perpignan, France; Hôpital Paris Saint Joseph, Paris, France; Pôle Ophtalmologique de la Clinique Mutualiste, Bordeaux, France; Santen Pharmaceuticals, Emeryville, CA, USA; University Eye Clinic, Maastricht University Medical Center, Maastricht, The Netherlands

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022